Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001178913-25-001595
Filing Date
2025-05-06
Accepted
2025-05-06 08:35:08
Documents
20

Document Format Files

Seq Description Document Type Size
1 424B3 zk2533123.htm 424B3 2529356
2 image00001.jpg GRAPHIC 4997
3 image00002.jpg GRAPHIC 42662
4 image00003.jpg GRAPHIC 7155
5 image00004.jpg GRAPHIC 24778
6 image00005.jpg GRAPHIC 29730
7 image00006.jpg GRAPHIC 30164
8 image00007.jpg GRAPHIC 34506
9 image00008.jpg GRAPHIC 28300
10 image00009.jpg GRAPHIC 24124
11 image00010.jpg GRAPHIC 27256
12 image00011.jpg GRAPHIC 22585
13 image00012.jpg GRAPHIC 38377
14 image00013.jpg GRAPHIC 28217
15 image00014.jpg GRAPHIC 28529
16 image00015.jpg GRAPHIC 22374
17 image00016.jpg GRAPHIC 25123
18 image00017.jpg GRAPHIC 21790
19 image00018.jpg GRAPHIC 17982
20 image00019.jpg GRAPHIC 2366
  Complete submission text file 0001178913-25-001595.txt   3167477
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-282556 | Film No.: 25915396
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)